Objective: To study the efficacy and safety of Shenfu injection(SFI) in combination with platinum-contained first-line chemotherapy in treating non-small cell lung cancer (NSCLC). Method: Cochrane library

PubMed

CBM

CNKI

VIP

WANFANG DATA and Traditional Chinese Medicine Database System were searched through computers. The search was finished in September

2012.Randomized controlled trials (RCTs) of SFI in combination with platinum-contained first-line chemotherapy (versus chemotherapy alone) in any language were included. Two researchers extracted data and assess literature quality separately

and made a meta-analyses by RevMan 5.1 software. Result: A Total of 19 RCTs was included. The Meta-analysis showed that compared with the pure application of platinum-contained first-line chemotherapy

the combination of SFI and chemotherapy can not enhance the near-term curative effect [OR=1.41

95%CI(0.98

2.02)

P=0.06]

but may improve the quality of life [OR=2.72

95% CI(1.48

5.00)

P=0.001]

enhance CD3+[SMD=0.41

95% CI(0.10

0.71)

P=0.008]

CD4+[SMD=7.58

95% CI(4.32

10.84)

P<0.000 01] and CD4+/CD8+[SMD=9.89

95% CI(4.76

15.02)

P=0.000 2] and reduced WBC toxicity [RR=0.35

95% CI(0.23

0.54)

P<0.000 01]

Hemoglobin toxicity(RR=0.41

95% CI:0.20~0.83

P=0.01)

Platelet toxicity [RR=0.34

95% CI(0.18

0.65)

P=0.001]

the gastrointestinal reactions [RR=0.24

95% CI(0.13

0.45)

P<0.000 01)]. Conclusion: The current evidence indicates that SFI can not enhance the chemotherapeutic effect on NSCLC patients

but may improve the quality of life and reduce adverse effect of contained therapy of platinum and chemotherapeutics. These results require confirmation with rigorously controlled trials.